1-3 of 3
Bogdan Muresan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia

Free
Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Ruth Mokgokong, Athina Palaka, Robert K. Hills, MA, DPhil, MSc, Nicholas Latimer, PhD, Bart Heeg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2712.
https://doi.org/10.1182/blood-2018-99-110800
Published: 2018
Journal Articles

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Free
Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Rocco J. Crescenzo, MD, Eric Leip, PhD, Andrea Viqueira, MD, Bart Heeg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1742.
https://doi.org/10.1182/blood-2018-99-114827
Published: 2018
Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Free
Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD
Journal: Blood
Blood (2016) 128 (22): 3095.
https://doi.org/10.1182/blood.V128.22.3095.3095
Published: 2016